<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22786667</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1520-6017</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>101</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2012</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pharmaceutical sciences</Title>
          <ISOAbbreviation>J Pharm Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Biowaiver monographs for immediate-release solid oral dosage forms: ketoprofen.</ArticleTitle>
        <Pagination>
          <StartPage>3593</StartPage>
          <EndPage>3603</EndPage>
          <MedlinePgn>3593-603</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jps.23233</ELocationID>
        <Abstract>
          <AbstractText>Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate-release (IR) solid oral dosage forms containing ketoprofen are reviewed. Ketoprofen's solubility and permeability, its therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions, and reported BE/bioavailability (BA)/dissolution data were taken into consideration. The available data suggest that according to the current Biopharmaceutics Classification System (BCS) and all current guidances, ketoprofen is a weak acid that would be assigned to BCS Class II. The extent of ketoprofen absorption seems not to depend on formulation or excipients, so the risk of bioinequivalence in terms of area under the curve is very low, but the rate of absorption (i.e., BE in terms of peak plasma concentration, C(max) ) can be altered by formulation. Current in vitro dissolution methods may not always reflect differences in terms of C(max) for BCS Class II weak acids; however, such differences in absorption rate are acceptable for ketoprofen with respect to patient risks. As ketoprofen products may be taken before or after meals, the rate of absorption cannot be considered crucial to drug action. Therefore, a biowaiver for IR ketoprofen solid oral dosage form is considered feasible, provided that (a) the test product contains only excipients present also in IR solid oral drug products containing ketoprofen, which are approved in International Conference on Harmonisation or associated countries, for instance, as presented in this paper; (b) both the test drug product and the comparator dissolve 85% in 30 min or less in pH 6.8 buffer; and (c) test product and comparator show dissolution profile similarity in pH 1.2, 4.5, and 6.8. When one or more of these conditions are not fulfilled, BE should be established in vivo.</AbstractText>
          <CopyrightInformation>Copyright Â© 2012 Wiley Periodicals, Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shohin</LastName>
            <ForeName>Igor E</ForeName>
            <Initials>IE</Initials>
            <AffiliationInfo>
              <Affiliation>Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kulinich</LastName>
            <ForeName>Julia I</ForeName>
            <Initials>JI</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramenskaya</LastName>
            <ForeName>Galina V</ForeName>
            <Initials>GV</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abrahamsson</LastName>
            <ForeName>Bertil</ForeName>
            <Initials>B</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kopp</LastName>
            <ForeName>Sabine</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Langguth</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Polli</LastName>
            <ForeName>James E</ForeName>
            <Initials>JE</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shah</LastName>
            <ForeName>Vinod P</ForeName>
            <Initials>VP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Groot</LastName>
            <ForeName>D W</ForeName>
            <Initials>DW</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barends</LastName>
            <ForeName>Dirk M</ForeName>
            <Initials>DM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dressman</LastName>
            <ForeName>Jennifer B</ForeName>
            <Initials>JB</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>07</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Pharm Sci</MedlineTA>
        <NlmUniqueID>2985195R</NlmUniqueID>
        <ISSNLinking>0022-3549</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004304">Dosage Forms</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005079">Excipients</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>90Y4QC304K</RegistryNumber>
          <NameOfSubstance UI="D007660">Ketoprofen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000042" MajorTopicYN="N">Absorption</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004304" MajorTopicYN="N">Dosage Forms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005079" MajorTopicYN="N">Excipients</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007660" MajorTopicYN="N">Ketoprofen</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013810" MajorTopicYN="N">Therapeutic Equivalency</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>4</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2012</Year>
          <Month>5</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2012</Year>
          <Month>5</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>7</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>7</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22786667</ArticleId>
        <ArticleId IdType="doi">10.1002/jps.23233</ArticleId>
        <ArticleId IdType="pii">S0022-3549(15)31368-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
